Gilead Sciences Inc (GILD)

[mick]

Gilead Sciences Inc (GILD)
71.67 ? -0.06 (-0.08%)
Volume: 6,556,960 @09/22/21 7:57:21 PM EDT
Bid Ask Day's Range
71.41 71.71 71.085 - 72.18
GILD Detailed Quote

[north40000]

NNVC encapsulates GILD’s Remdesivir, in what seems to be a proprietary formulation, and finds it remains intact longer, and works better, in Covid-19 treatment. Animal study reported by TDA news.

[Jasbg]

north, This is all on Fauci - proving all the lies used against 45 and "anecdotal" use of Hydroxychloroquine saving Covid-19 patients.

In the end it were all about money - and Remdesivir were in the middle of the bedrail. Right from the start Chinese came out and said Remdesivir didn't stop the infection - still it was approved for treating Covid patients by FDA - while HCQ at the same time were banned from use.

https://www.thegatewaypundit.com/2020/08/jail-fauci-us-almost-30-times-covid-19-deaths-per-population-third-world-countries-promoted-early-hcq-use/

[north40000]

European study finds that Gilead's Covid-19 antiviral remdesivir shows no clinical benefit

September 17, 2021 07:29 AM EDTUpdated 08:17 AM Coronavirus
European study finds that Gilead's Covid-19 antiviral remdesivir shows no clinical benefit

Nicole DeFeudis
Editor

Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid-19. But new data from a European study suggest the drug, which has been given to about half of hospitalized Covid patients in the country, has no actual benefit.

The open-label DisCoVeRy trial enrolled Covid-19 patients across 48 sites in Europe to test a handful of treatments, including remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, and hydroxychloroquine. To participate, patients had to show symptoms for seven days and require oxygen support. A total of 429 patients were randomized to receive remdesivir plus standard of care, while 428 were assigned to standard of care alone.

Researchers measured remdesivir’s efficacy on day 15, using the World Health Organization’s seven-point scale — only to find that no clinical benefit was observed in patients who received the drug over those who got standard of care alone. And while previous studies have linked remdesivir to a faster time to recovery, that result was not seen in the DisCoVeRy trial.

Here’s how patients were distributed on the WHO’s scale:

Not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]).

The results bring into question Veklury’s approval — and also its hefty $3,000-plus price tag.

The FDA granted remdesivir full approval back in October based on three randomized control studies, including the full data from the NIAID-sponsored Phase III ACTT-1 trial published on Oct. 8, according to Gilead. That study showed a reduction in recovery time by five days in hospitalized Covid-19 patients and by seven days in patients requiring oxygen.

Gilead had previously been granted a partial EUA in early May to treat severe Covid-19, which was later expanded in August to include all hospitalized adults and children after a Gilead-led study showed modest efficacy.

But the week before remdesivir was approved, the WHO released a study showing the antiviral had no substantial effect on improving mortality rates, reducing the amount of patients needing ventilators or shortening hospital stays. In this trial, remdesivir had no material effects on ventilation initiation or time to discharge.

In an FAQ, the FDA had said that since Gilead’s ACTT-1 study was randomized, double-blinded and placebo-controlled (whereas the WHO trial was open-label), they found ACTT-1 to be “better suited” in a time to recovery endpoint.

In April, Gilead CEO Dan O’Day said about half of all hospitalized patients with Covid-19 in the US are treated with Veklury.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

[dhbuzz]

Oral version of Gilead's remdesivir demonstrates promising preclinical results
Sep. 15, 2021 8:29 AM ETGilead Sciences, Inc. (GILD)Merck & Co., Inc. (MRK)By: Jonathan M Block, SA News Editor5 Comments
Pack of Remdesivir pills
AlexSava/E+ via Getty Images
An oral version of a prodrug of the parental nucleoside of Gilead's (NASDAQ:GILD) antiviral remdesivir showed promise in a preclinical study.
The prodrug, GS-621763, demonstrated antiviral activity both in lung cell lines and in mice infected with SARS-CoV-2, according to results published in bioRxiv. The results have yet to be peer reviewed.
GS-621763 was also compared against molnupiravir, Merck's (NYSE:MRK) oral antiviral that the company expects will receive Emergency Use Authorization for COVID-19 by the end of the year, and both drugs had similar efficacy.
In the U.S., Veklury (remdesivir) is indicated for adults and children 12 years of age and older for the treatment of COVID-19 requiring hospitalization.
Now Read: Gilead: Fundamentals With A Booster Shot

[dhbuzz]

iT STARTED IN LATE 2020...https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/387/matinas-biopharma-announces-collaboration-with-the-national

[dhbuzz]

https://www.griproom.com/fun/gilead-and-matinas-may-have-beaten-covid-19

[dhbuzz]

I BELIEVE GILD is working with MTNB on this.

[north40000]

https://finance.yahoo.com/news/gilead-sciences-wins-reversal-1-154757453.html

"... A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

The two companies have been embroiled in a case involving accusations that Yescarta, the CAR-T cell cancer immunotherapy from Gilead's Kite Pharma unit, infringed on a patent for a similar therapy from Bristol's Juno Therapeutics.

Last year, a federal judge increased the damages from a jury trial and ordered Gilead to pay Bristol Myers $1.2 billion in the patent infringement case. The ruling on Thursday by the U.S. Court of Appeals for the Federal Circuit reversed the decision.

Bristol Myers in a statement said it disagreed with latest ruling and would seek a review of the Federal Circuit’s decision."

http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1758.OPINION.8-26-2021_1825257.pdf

[mick]

Gilead Sciences Inc (GILD)
71.16 ? 0.28 (0.40%)
Volume: 4,361,771 @08/13/21 7:42:04 PM EDT
Bid Ask Day's Range
71.1 71.16 70.76 - 71.39
GILD Detailed Quote

[mick]

Gilead Sciences Inc (GILD)
68.1 ? 0.41 (0.61%)
Volume: 6,419,563 @07/09/21 6:39:18 PM EDT
Bid Ask Day's Range
68.02 68.44 67.454 - 68.41
GILD Detailed Quote

[Newc]

Interesting article…

https://insiderfinancial.com/enzolytics-enzc-takes-on-hiv-heavyweight-gilead-sciences/181723/

[mick]

Gilead Sciences Inc (GILD)
66.1543 ? -0.0757 (-0.11%)
Volume: 2,473,973 @05/26/21 11:55:31 AM EDT
Bid Ask Day's Range
66.15 66.16 65.55 - 66.225
GILD Detailed Quote

[north40000]

Is GILD's remdesivir relevant to this COVID-19 Vascular MOA? Amarin's Vascepa could be:

https://scitechdaily.com/covid-19-is-a-vascular-disease-coronavirus-spike-protein-attacks-vascular-system-on-a-cellular-level/

SALK Institute and NIH research report

DOI: 10.1161/CIRCRESAHA.121.318902

https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318902

[mick]

[Stowe]

http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

[DewDiligence]

The tested cocktails still require (intravenous) remdesivir to stop SARS-CoV-2 replication. What's badly needed is an all-oral regimen.

[Stowe]

Add some of this.https://www.sciencedaily.com/releases/2021/04/210427113805.htm

[tikotiko]

Another step in the right direction:

https://www.fdanews.com/articles/202455-advocacy-group-calls-for-rescinding-remdesivirs-approval-as-covid-19-treatment

[tikotiko]

More news about Redemsideath’s suspension:

https://www.reuters.com/article/us-health-coronavirus-remdesivir-who-sus-idUKKBN2801MU

Time to call Dr. Faucci to come to the rescue?

[tikotiko]

News from India regarding Redemsivdeath:

https://www.indiatoday.in/coronavirus-outbreak/story/who-suspends-remdesivir-from-list-of-medicines-1742697-2020-11-20

[mick]

Gilead Sciences Inc (GILD)
66.87 ? 1.1 (1.67%)
Volume: 7,789,761 @04/16/21 7:59:31 PM EDT
Bid Ask Day's Range
60.55 68.6 65.965 - 67.08
GILD Detailed Quote

[mick]

GILD Investor Relations
http://investors.gilead.com/events?c=69964&p=irol-calendar
Viral Disease Pipeline Phase 1 Phase 2 Phase 3 NDA/BLA/MAA HIV Biktarvy HIV treatment pediatric1 Capsid inhibitor (GS-6207)
HIV HTE HIV treatment naïve Vesatolimod (GS-9620, TLR-7 agonist) HIV cure Elipovimab (GS-9722, bNAb)
HIV cure HBV Selgantolimod
(GS-9688,TLR-8 agonist) HBV cure PD-L1 inhibitor (GS-4224) HBV cure 1 Biktarvy HIV treatment pediatric label extension.
2 Registrational for heavily treatment-experienced (HTE) patients.

http://investors.gilead.com/stock-information/stock-quote-chart
http://investors.gilead.com/stock-information/historical-price-lookup

[tikotiko]

News from India:
https://news.yahoo.com/india-bans-exports-remdesivir-drug-044405093.html
The Remdesivdeath gig is up. There are better options...

[north40000]

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study
Clinical improvement was observed over and above other treatments, including steroids and/or remdesivir
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005301/en/

[Taurus69]

$gild $64.46 ^ 0.38 (0.59%)
Volume: 15,231,389 @03/19/21 5:59:44 PM EDT

[Tamtam]

There are good/very good treatments but not yet FDA approved for covid 19

It are not vaccines but one vaccine ( Astrazeneca) that are on hold but not cancelled. in Europe

[MrGlasses]

Covid-No good treatments after 1 year?

Nothing but vaccines that are getting cancelled all over Europe. And those that aren't, how long do they last? A few months/weeks??

Meanwhile, crisis mode in Brazil as Brazilians begging for a treatment that works.

Brazil plunges into deadliest chapter of it's pandemic
March 13, 2021
https://www.theguardian.com/world/2021/mar/13/brazil-covid-coronavirus-deaths-cases-bolsonaro-lula

[bob4uall]

Except for GILD, all 2 dozen or so of my investments have gains so far today. That is , except for SDOW, which is a little crash insurance in my portfolio.

GILD has been a long hold that has gone nowhere for a few years for me. I guess I'll sell it when it finally rallies a little. Their culture is a little too woke for me anyway. I mean, some social conscience is a good thing, but one can go too far.

[Tamtam]

Gilead Sciences Completes Acquisition of MYR GmbH
https://ih.advfn.com/stock-market/NASDAQ/gilead-sciences-GILD/stock-news/84499688/gilead-sciences-completes-acquisition-of-myr-gmbh

[north40000]

An opportunity:

https://investor.amarincorp.com/static-files/be442dfe-bb2d-47b8-bb17-f56bcbee3755

https://amarincorp.gcs-web.com/static-files/db64bd4e-1417-438f-be20-381de9358c40


https://investor.amarincorp.com/static-files/da0acd44-8e86-4b60-ad12-2b85b59fa69f

[name]

The Gild price is dropping recently. It has a lot of good news as you posted and 3/5/2021, FDA will have a meeting to discussion of the drug ( Axicabtagene ciloleucel ) for Getting Label Expansion For Cell-Therapy to Treat Lymphoma. Is some thing wrong?

[Michel]

https://www.mdpi.com/1999-4915/13/2/271

maybe a partnership would be "necessary"?

http://www.ipharminc.com/press-release/2021/3/2/innovation-pharmaceuticals-announces-publication-of-peer-reviewed-scientific-article-in-the-journal-viruses-on-the-anti-sars-cov-2-properties-of-brilacidin

http://www.ipharminc.com/press-release/2021/2/26/innovation-pharma-provides-study-details-for-ongoing-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients

[mick]

Gilead Sciences Inc (GILD)
64.38 ? -0.85 (-1.30%)
Volume: 6,054,624 @02/19/21 7:59:23 PM EST
Bid Ask Day's Range
64.38 64.72 64.27 - 65.22
GILD Detailed Quote

[Taurus69]

$gild $64.38 v -0.85 (-1.30%)
Volume: 6,052,396 @02/19/21 6:25:34 PM EST

[SimbaJ22]

GILD was hash tagged by our COO on Twitter and new development points us toward ur direction. Hopefully, GILD takes down their previous partner and tamiflu with ENZC ITV-1. Just a thought and my opinion.

$enzc. $GILD investors. You might want to check out this PR today. From googling found that tamiflu used to be owned by @Gilead until some bad blood. Key here is our drug was tested against tamiflu and was 20x less toxic with same efficacy. #payback maybe? https://t.co/yixxbz7EgL

— SimbaJ22 (@SimbaJ22) February 16, 2021

https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Reports-Test-Results-of-its-Patented-ITV-1-Conducted-at-the-National-Centre-of-Infectious-and-Parasitic-D?id=290078

[Tamtam]

Little chance of that

[PennyStocksGuru]

Let me know when it gets under $60.

[north40000]

In November 2019, Dew Diligence posted the following on the BT Value board about a GILD/Amarin "collaboration":

"Quote:
…GILD added Vascepa to NASH trial…
An earlier article in streetinsider.com was guilty of suggesting that GILD had some kind of partnership with AMRN, so an updated article was posted to rebut this notion:

https://www.streetinsider.com/Analyst+Comments/Amarin+%28AMRN%29+Smacked+on+Bearish+Call%2C+But+Gilead+%28GILD%29+Adding+Vascepa+to+its+NASH+Combo+Raises+Eyebrows/16159446.html
Quote:
A recent posting at clinicaltrials.gov, pointed out by Raymond James' Gilead analyst Steven Seedhouse, showed that a cohort was added to the protocol that includes Amarin's Vascepa along with firsocostat (ACC inhibitor) and cilofexor (FXR agonist).

The analyst thinks Vascepa was added to compensate for the increase in TGs caused by firsocostat. He said this is similar to how statins compensate for LDL-C increase by FXR agonists.

Seedhouse said he is not aware of any formal collaboration between Amarin and Gilead, so he presumes Gilead is purchasing drug material."

I am trying to obtain any news of what has happened with respect to results from the added Vascepa mentioned in the above-quoted material. Comments from anyone with specific knowledge would be appreciated. Our portfolios contain both GILD and AMRN.

The FDA approved Vascepa for reducing the risk from various aspects of CVDs last December 2020.

See also:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155960148

[Purple Wonder]

Remdesevir has FDA approval! Check your facts before spamming another board for a different play.

With as many doses that have been produced and ordered by the world by Gilead's extensive production network, it will take years for your B to ramp up and see meaningful revenue results when comparing the 2.

Having said that, I am a buyer of I*** based on Ph 2 results which have not been announced to have started yet, only plans to start. Initial dosing would be something to put out and that was supposed to have happened last week.


https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

[Ultimate01]

Gilead’s Remdesivir AKA Velkury has emergency use authorization (EUA) n the United States and just barely reduces hospital length of stay in some patients and it is questionable if it really reduces mortality to any degree. It has NOT received FDA approval because it hasn’t performed in real life practice. As soon as the FDA sees another drug that can reduce length of stay and save some lives, Remdesivir will lose it’s EUA and it’s share of the market which is pretty much all of it.

Remdesivir needs Brilacidin, but it is abundantly clear that Brilacidin does not need Remdesivir. I anticipate the placebos will be whatever the standard of care is being used in the respective country as it is unethical to withhold treatment in a life or death situation. Brilacidin will go head to head vs. Remdesivir and we all know who will win.


Efftiabdunnsunnylemonturds!

[mick]

https://otcbb.swingtradebot.com/equities/GILD

N.Y. , NASDAQ
https://swingtradebot.com/equities/GILD

[Taurus69]

$gild $65.16 ^ 0.48 (0.74%)
Volume: 11,724,091 @01/29/21 7:57:47 PM EST

[roofus krile]

Wake up call on Brazil\S.America COVID Reinfection. Brazil Govt Is Working With PDSB On Second Vaccine ...

[RJ5]

Good post, and very positive news for the markets

[Tamtam]

A national Covid strategy.
A good part of the orders Biden has signed so far relate to the coronavirus pandemic. The Current administration is building a muscular federal response to the crisis, a major change from Trump’s decentralized approach. The Biden plan will include a Pandemic Testing Board to establish unified standards across the country and boost supplies, which are still inadequate. There will be a Federal vaccination campaign, with federaly run mass vaccination centers and mobile units for rural areas. States and cities will get more funding and personnel for speedy vaccine deployment. The Biden administration will rebuild scientific agencies that Trump shackled or gutted. It will also establish procedures for reopening schools and provide more resources for local school districts.

It’s a mystery why the previous administration didn’t take these types of steps early in the pandemic. Public health experts and business leaders have stressed all along that massively scaled testing is crucial to safely operating businesses and reopening those forced to close. Vaccines will ultimately reduce the need for testing, but the vaccine rollout has been slow since it kicked off in December, with widespread immunity not likely until 2022 at the current pace.

[Tamtam]

Impressive score

[livefree_ordie]

Final Score Brilacidin 426, Remdesivir 130 .... a complete BLOW OUT!

Statistical Facts in Medical Science do matter!

BRILACIDIN SI *426*. Some keep babbling about safety.
Government RBLs recently declared BRILACIDIN has a SI of *426*.
Everyone was hoping to at least equal Gileads Remdesivir number of 129.87. A number good enough for FDA APPROVAL and 2 billion in revenues last year.
The higher the SI ratio the more EFFECTIVE and SAFE a drug would be during treatment for viral infections.
SAFE and EFFECTIVE are the key words.
The SI of a compound IS widely accepted parameter used to express a compounds efficacy in the INHIBITION of virus replication.

BRILACIDIN *426* efficiency has a 97% kill rate of the virus in lab testing. When combined with Remdesivir's 129 the kill rate did slightly jump up to 99.85%.
Simply put, peple would being saved at this very moment IF Gilead
was owner of BRILACIDIN *426*.

Seeing is believing. BRILACIDIN did so well that the RBLs STATED that BRILACIDIN should be lab tested against a host of other viruses.
You can believe what the major UNIVERSITIES, Government RBLs and highly honored scientists are saying after testing BRILACIDIN in the labs or you can belive the unsubstantiated claims of the other side. The agenda of the first group is to better society and bring help to the medical community. I can't say what the agenda is of the other side. God only knows..

BRILACIDIN *426* the SAFE ALTERNAIVE to many future ailments...

[BottomBounce]

$GILD upgraded to $83.00

[Taurus69]

$gild $60.0 v -0.11 (-0.18%)
Volume: 13,251,119 @01/05/21 7:59:23 PM EST